IPP Bureau
FDA grants priority review to Tzield for youngest Type 1 diabetes patients
By IPP Bureau - January 07, 2026
Currently approved for patients eight and older, Tzield could now be used to delay the onset of stage 3 type 1 diabetes (T1D) in children diagnosed with stage 2 T1D
GSK’s Nucala approved in China for COPD with high eosinophils
By IPP Bureau - January 07, 2026
Mepolizumab is the first and only monthly biologic in China tested for COPD patients with blood eosinophil counts (BEC) as low as 150 cells/µL
Incyte eyes first-line nod for Tafasitamab in aggressive lymphoma
By IPP Bureau - January 07, 2026
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma (NHL) in adults, represents 40% of all cases worldwide
.jpg "MetaVia’s DA-1726 shows breakthrough weight loss in Phase 1 trial"){kind=logo}
MetaVia’s DA-1726 shows breakthrough weight loss in Phase 1 trial
By IPP Bureau - January 07, 2026
Fasting glucose improved by 12.3 mg/dL, while liver stiffness dropped 23.7%, signaling a direct hepatic benefit
Medera doses final patient in high-dose HFpEF gene therapy trial
By IPP Bureau - January 07, 2026
Heart failure affects an estimated 64.3 million people worldwide
WuXi Biologics secures ISO 20400 certification
By IPP Bureau - January 07, 2026
WuXi Biologics has integrated sustainability principles throughout its supplier lifecycle management
Kelun-Biotech secures IND nod for innovative cancer therapy SKB105 in China
By IPP Bureau - January 07, 2026
Kelun-Biotech and Crescent Biopharma forged a collaboration covering SKB105/CR-003 and SKB118, a PD-1 x VEGF bispecific antibody also known as CR-001
Avient introduces non-PFAS GlideTech formulations for catheters
By IPP Bureau - January 07, 2026
GlideTech materials are available in several standard base resins and offer customization options for specific applications
Merck completes acquisition of Cidara Therapeutics
By IPP Bureau - January 07, 2026
Cidara will become a wholly owned subsidiary of Merck and the common stock of Cidara will no longer be listed or traded on the Nasdaq Global Market
Jubilant Ingrevia appoints Pravesh Kumar Garg as Chief of Manufacturing
By IPP Bureau - January 06, 2026
Pravesh brings with him over 29 years of experience in leading complex manufacturing operations and driving operational excellence
Thyrocare appoints Rajdeep Panwar as Chief Commercial Officer
By IPP Bureau - January 06, 2026
Rajdeep is an accomplished business leader with a strong techno-commercial background in the healthcare and diagnostic sector
Wegovy pill marks first GLP-1 weight-loss medicine in oral form
By IPP Bureau - January 06, 2026
The approval introduces a needle-free alternative to injectable GLP-1 therapies
PHARMEXCIL holds high-level talks with government to boost India’s pharma exports
By IPP Bureau - January 06, 2026
India’s pharmaceutical sector stands at a pivotal inflection point
Corewell Health, Quest Diagnostics finalize Michigan Lab JV
By IPP Bureau - January 06, 2026
The state-of-the-art laboratory opens at the Corewell Health Southfield Center in early 2027
Dabur sees early demand recovery, rural sales lead growth in Q3 FY26
By IPP Bureau - January 06, 2026
Within India, Dabur expects its Home & Personal Care business to deliver double-digit growth,
